Michael S Diamond Selected Research

Ligands

1/2021	Enteric helminth coinfection enhances host susceptibility to neurotropic flaviviruses via a tuft cell-IL-4 receptor signaling axis.
1/2017	MAVS Is Essential for Primary CD4+ T Cell Immunity but Not for Recall T Cell Responses following an Attenuated West Nile Virus Infection.
1/2016	Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late.
12/2015	RIG-I Signaling Is Essential for Influenza B Virus-Induced Rapid Interferon Gene Expression.
1/2014	Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection.
8/2013	Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors.
9/2012	CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons.
9/2007	CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael S Diamond Research Topics

Disease

255	Infections 05/2024 - 12/2002
79	West Nile Fever 02/2024 - 12/2003
67	COVID-19 05/2024 - 01/2020
62	Virus Diseases (Viral Diseases) 02/2024 - 12/2002
24	Inflammation (Inflammations) 01/2023 - 02/2008
23	Dengue (Dengue Fever) 11/2021 - 12/2002
22	Zika Virus Infection 01/2021 - 01/2016
16	Flavivirus Infections 01/2021 - 12/2002
12	Encephalitis (Encephalitis, Rasmussen) 01/2023 - 11/2006
11	Viremia 01/2020 - 12/2003
11	Arthritis (Polyarthritis) 01/2020 - 12/2013
10	Vesicular Stomatitis 01/2022 - 01/2012
7	Weight Loss (Weight Reduction) 02/2022 - 01/2020
7	Coinfection 01/2021 - 09/2010
6	Breakthrough Infections 02/2024 - 08/2021
6	Alphavirus Infections 01/2023 - 01/2018
6	Neoplasms (Cancer) 11/2021 - 11/2018
6	Yellow Fever 12/2020 - 05/2008
5	Human Influenza (Influenza) 01/2023 - 09/2003
5	Japanese Encephalitis 11/2020 - 05/2008
5	Severe Dengue 01/2012 - 12/2007
4	Pneumonia (Pneumonitis) 02/2022 - 12/2020
4	Communicable Diseases (Infectious Diseases) 05/2021 - 01/2014
4	Bites and Stings (Sting) 10/2020 - 07/2012
3	Respiratory Tract Infections (Respiratory Tract Infection) 02/2024 - 01/2022
3	Coronavirus Infections 01/2022 - 12/2020
3	Lung Diseases (Lung Disease) 12/2020 - 07/2020
3	Persistent Infection 01/2020 - 01/2016
3	Melanoma (Melanoma, Malignant) 01/2017 - 05/2006
3	Thrombocytopenia (Thrombopenia) 09/2015 - 02/2010
2	Ebola Hemorrhagic Fever 11/2023 - 04/2017
2	Primary Immunodeficiency Diseases 01/2022 - 01/2022
2	Zoonoses 01/2022 - 12/2021
2	Weight Gain 01/2022 - 06/2021
2	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 10/2017
2	Severe Acute Respiratory Syndrome 04/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

100	VaccinesIBA 05/2024 - 12/2003
76	AntibodiesIBA 04/2023 - 02/2003
74	Antiviral Agents (Antivirals)IBA 02/2024 - 12/2002
72	Proteins (Proteins, Gene)FDA Link 02/2024 - 07/2005
65	Monoclonal AntibodiesIBA 05/2024 - 03/2005
37	Neutralizing AntibodiesIBA 03/2024 - 03/2006
36	InterferonsIBA 02/2024 - 01/2003
29	EpitopesIBA 01/2022 - 05/2005
26	CytokinesIBA 03/2024 - 09/2008
25	Interferon Type IIBA 01/2022 - 09/2008
22	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2002
21	AntigensIBA 01/2022 - 12/2003
20	Immunoglobulin G (IgG)IBA 01/2023 - 12/2003
16	Complement System Proteins (Complement)IBA 01/2022 - 01/2003
15	Glycoproteins (Glycoprotein)IBA 01/2022 - 09/2005
14	mRNA VaccinesIBA 01/2024 - 01/2017
13	Messenger RNA (mRNA)IBA 01/2024 - 07/2013
12	ChemokinesIBA 03/2024 - 09/2005
10	Viral RNAIBA 12/2020 - 12/2002
9	Transcription Factors (Transcription Factor)IBA 11/2017 - 09/2011
9	Immunoglobulin M (IgM)IBA 07/2015 - 02/2003
8	Broadly Neutralizing AntibodiesIBA 05/2024 - 01/2016
8	LigandsIBA 01/2021 - 09/2007
7	COVID-19 VaccinesIBA 05/2024 - 12/2020
7	IgG Receptors (Fc gamma RI)IBA 01/2023 - 02/2006
7	Peptides (Polypeptides)IBA 01/2020 - 01/2006
7	Interferon-betaIBA 12/2015 - 03/2005
6	2019-nCoV Vaccine mRNA-1273IBA 05/2024 - 01/2022
6	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 03/2005
6	Phosphotransferases (Kinase)IBA 06/2020 - 12/2011
5	Interferon LambdaIBA 01/2021 - 04/2015
5	Blocking AntibodiesIBA 01/2018 - 02/2013
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2012 - 09/2008
4	COV2-2130IBA 04/2023 - 01/2020
4	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022 - 01/2022
4	SARS-CoV-2 spike proteinIBA 01/2022 - 03/2021
4	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022 - 01/2022
4	EnzymesIBA 11/2020 - 11/2008
4	Explosive Agents (Explosives)IBA 01/2020 - 08/2014
4	Interferon Regulatory FactorsIBA 10/2014 - 09/2008
4	LectinsIBA 07/2011 - 10/2009
3	Immunoglobulins (Immunoglobulin)IBA 02/2024 - 11/2008
3	Combined VaccinesIBA 09/2022 - 01/2020
3	FurinIBA 01/2021 - 11/2011
3	Polysaccharides (Glycans)IBA 11/2020 - 08/2010
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2015
3	LipidsIBA 10/2019 - 01/2017
3	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2019 - 09/2015
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2017 - 05/2006
3	c-Mer Tyrosine KinaseIBA 01/2017 - 12/2015
3	Pattern Recognition ReceptorsIBA 10/2015 - 11/2013
3	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 03/2011 - 08/2010
2	cilgavimab and tixagevimab drug combinationIBA 05/2024 - 01/2022
2	2-5A-dependent ribonuclease (RNase L)IBA 02/2024 - 07/2006
2	NanovaccinesIBA 02/2024 - 03/2021
2	Angiotensin-Converting Enzyme 2IBA 12/2022 - 01/2021
2	K-18 conjugate (K18)IBA 12/2022 - 11/2020
2	JIB-04IBA 01/2022 - 06/2021
2	COV2-2196IBA 01/2022 - 01/2020
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022 - 12/2021
2	Mesalamine (Mesalazine)FDA LinkGeneric 01/2022 - 08/2021
2	ImmunosorbentsIBA 11/2020 - 01/2015

Therapy/Procedure

56	Therapeutics 09/2023 - 12/2002
4	Intranasal Administration 01/2023 - 10/2020